Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 8Pancreatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Neoplasms 4Melanoma 3Gastrointestinal Neoplasms 3Cholangiocarcinoma 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Neoplasms by Site 2Multiple Myeloma 2Hematologic Neoplasms 2Gallbladder Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thrombocytosis 1Thoracic Neoplasms 1Skin Neoplasms 1Sarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Adenocarcinoma 1Noonan Syndrome 1

Interventions

Gemcitabine 95Cisplatin 72Capecitabine 39Oxaliplatin 38durvalumab 29Fluorouracil 27pembrolizumab 26Leucovorin 23S 1 (combination) 19Nivolumab 14Irinotecan 14lenvatinib 13Bevacizumab 13tremelimumab 10130-nm albumin-bound paclitaxel 9apatinib 8Trastuzumab 7Injections 7Immune Checkpoint Inhibitors 7Docetaxel 7Albumin-Bound Paclitaxel 7Paclitaxel 6Drug Therapy 6titanium silicide 5surufatinib 5irinotecan sucrosofate 5gemcitabine-oxaliplatin regimen 5envafolimab 5camrelizumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × cobimetinib × Gastrointestinal × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡